A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
167/103.2
A61K 35/14 (2006.01) A61K 38/20 (2006.01)
Patent
CA 1297002
-28- ABSTRACT The present invention discloses a new approach to the therapy of cancer in humans based on the administration of lymphokine activated killer (LAK) cells and interleukin-2 (IL-2). Twelve patients with metastatic cancer who had failed standard available therapy were treated. LAK cells were generated from peripheral blood mononuclear cells obtained at multiple leukaphereses and incubated in the recombinant-derived lymphokine, IL-2. Following three to four days of incubation in IL-2, the resulting LAK cells were capable of lysing fresh tumor cells but not normal cells. These LAK cells were reinfused into the autologous patient, along with the intravenous administration of recombinant IL-2 every 8 hours. Patients received up to 90 doses of IL-2 and from 2.8 to 12.6 x 1010 activated cells from up to 14 sequential leukaphereses. Six patients showed objective regression of established cancer.
515585
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
U.s. Departm Ent Of Commerce The United States Of America Represented By The Secretary
LandOfFree
Adoptive immunotherapy as a treatment modality in humans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adoptive immunotherapy as a treatment modality in humans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adoptive immunotherapy as a treatment modality in humans will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1335849